Literature DB >> 20516525

Complications of HIV disease and antiretroviral treatment.

Anne F Luetkemeyer1, Diane V Havlir, Judith S Currier.   

Abstract

There is growing interest in the pathogenesis, treatment, and prevention of long-term complications of HIV disease and its therapies. Specifically, studies focused on cardiovascular, renal, bone, and fat abnormalities were prominent at the 17th Conference on Retroviruses and Opportunistic Infections. Although enthusiasm about the effectiveness of current antiretroviral therapy remains strong, collectively, the ongoing work in the area of HIV disease and treatment complications appears to reflect concerns that these clinical problems will continue to remain important and possibly increase over time in the current therapeutic era. This year's conference also highlighted important data on prevention and optimal treatment of common coinfections that occur in HIV-infected individuals, including tuberculosis, influenza, and viral hepatitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20516525      PMCID: PMC3032798     

Source DB:  PubMed          Journal:  Top HIV Med        ISSN: 1542-8826


  12 in total

1.  Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection.

Authors:  Martin S Hirsch; Roy T Steigbigel; Scholomo Staszewski; Deborah McMahon; Margaret A Fischl; Bernard Hirschel; Kathleen Squires; Mark J DiNubile; Charlotte M Harvey; Joshua Chen; Randi Y Leavitt
Journal:  Clin Infect Dis       Date:  2003-09-18       Impact factor: 9.079

2.  Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N.

Authors:  Katarina Gyllensten; Filip Josephson; Knut Lidman; Maria Sääf
Journal:  AIDS       Date:  2006-09-11       Impact factor: 4.177

3.  The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients.

Authors:  Angelo Sangiovanni; Gian Maria Prati; Pierangelo Fasani; Guido Ronchi; Raffaella Romeo; Matteo Manini; Ersilio Del Ninno; Alberto Morabito; Massimo Colombo
Journal:  Hepatology       Date:  2006-06       Impact factor: 17.425

4.  Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

Authors:  F Degos; C Christidis; N Ganne-Carrie; J P Farmachidi; C Degott; C Guettier; J C Trinchet; M Beaugrand; S Chevret
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

5.  Association of C-reactive protein and HIV infection with acute myocardial infarction.

Authors:  Virginia A Triant; James B Meigs; Steven K Grinspoon
Journal:  J Acquir Immune Defic Syndr       Date:  2009-07-01       Impact factor: 3.731

6.  Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine.

Authors:  Roy M Gulick; Anne Meibohm; Diane Havlir; Joseph J Eron; Audrey Mosley; Jeffrey A Chodakewitz; Robin Isaacs; Charles Gonzalez; Deborah McMahon; Douglas D Richman; Michael Robertson; John W Mellors
Journal:  AIDS       Date:  2003-11-07       Impact factor: 4.177

7.  Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.

Authors:  Jussi Sutinen; Ulrich A Walker; Ksenia Sevastianova; Hartwig Klinker; Anna-Maija Häkkinen; Matti Ristola; Hannele Yki-Järvinen
Journal:  Antivir Ther       Date:  2007

8.  Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells.

Authors:  Ulrich A Walker; Nils Venhoff; Eva C Koch; Manfred Olschewski; Josef Schneider; Bernhard Setzer
Journal:  Antivir Ther       Date:  2003-10

9.  Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D.

Authors:  Todd T Brown; Grace A McComsey
Journal:  Antivir Ther       Date:  2010       Impact factor: 1.679

10.  Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.

Authors:  Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton
Journal:  PLoS Med       Date:  2008-10-21       Impact factor: 11.069

View more
  1 in total

1.  Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study.

Authors:  Zvenyika Ar Gomo; James G Hakim; Sarah A Walker; Willard Tinago; Gibson Mandozana; Cissy Kityo; Paula Munderi; Elly Katabira; Andrew Reid; Diana M Gibb; Charles F Gilks
Journal:  AIDS Res Ther       Date:  2014-10-02       Impact factor: 2.250

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.